An Arterial-Enhancing Liver Nodule With Washout in a Patient With Metabolic and Alcohol-Associated Liver Disease - Report - MDSpire

A Liver Nodule Exhibiting Arterial Enhancement and Washout in a Patient with Alcohol-Related and Metabolic Liver Disease

  • By

  • Soon Kyu Lee

  • Sun Young Jun

  • Young Chul Yoon

  • July 1, 2026

Share

Clinical Report: A Liver Nodule Exhibiting Arterial Enhancement and Washout

Background

Liver nodules can present diagnostic challenges, particularly in patients with underlying liver disease. Differentiating between various types of hepatic tumors is crucial for appropriate management, especially in cases where imaging suggests malignancy. Primary hepatic GISTs are exceedingly rare, with only approximately 40 cases reported in the literature.

Data Highlights

No numerical or trial data presented in the article.

Key Findings

  • A 5.3-cm hepatic nodule was detected in a patient with MetALD.
  • Dynamic contrast-enhanced MRI showed arterial phase hyperenhancement and washout, consistent with LI-RADS 5.
  • Histopathological analysis revealed spindle-shaped tumor cells, confirming a diagnosis of primary hepatic GIST.
  • The patient underwent laparoscopic left hemihepatectomy followed by adjuvant imatinib therapy.
  • Primary hepatic GISTs are exceedingly rare.

Clinical Implications

Clinicians should consider rare hepatic tumors like GIST in patients with chronic liver disease when imaging suggests HCC. Accurate diagnosis is essential for determining the appropriate treatment strategy.

Conclusion

This case highlights the importance of considering a broad differential diagnosis for hepatic nodules in patients with complex liver disease histories.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. European Radiology, 2025 -- Imaging Characteristics of Newly Recognized Low-Grade Vascular Tumors in the Liver: Hepatic Small Vessel Neoplasm and Anastomosing Hemangioma
  5. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma, 2025 -- Guidelines
  6. Imaging-based diagnosis of hepatocellular carcinoma
  7. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
  8. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel
  9. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
  10. ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer - PubMed
  11. A multisociety Delphi consensus statement on new fatty liver disease nomenclature - PubMed
  12. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary - PMC
  13. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update | Journal of Clinical Oncology
  14. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial - PubMed
  15. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. | Journal of Clinical Oncology
  16. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Original Source(s)

Related Content